Vertex Pharmaceuticals (BSP:VRTX34) EPS (Basic) : R$-3.23 (TTM As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Vertex Pharmaceuticals EPS (Basic)?

Vertex Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was R$5.61. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was R$-3.23.

Vertex Pharmaceuticals's EPS (Diluted) for the three months ended in Sep. 2024 was R$5.55. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was R$-3.41.

Vertex Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2024 was R$6.06. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -0.14.

During the past 12 months, Vertex Pharmaceuticals's average EPS without NRIGrowth Rate was -96.50% per year. During the past 3 years, the average EPS without NRI Growth Rate was 13.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 32.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Vertex Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 84.40% per year. The lowest was -96.70% per year. And the median was -1.25% per year.

Vertex Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Vertex Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals EPS (Basic) Chart

Vertex Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

4.70

13.43

12.85

17.01

17.21

Vertex Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															4.95	4.61	5.30	-18.74	5.61

Vertex Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Vertex Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(17735.316	-	0)	/	1030.800
	=	17.21

Vertex Pharmaceuticals's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(5789.216	-	0)	/	1032.000
	=	5.61

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-3.23

Vertex Pharmaceuticals (BSP:VRTX34) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Vertex Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Vertex Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (BSP:VRTX34) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

VRTX:USA VRTX:Mexico 1VRTX:Italy 0QZU:UK VX1:Germany VX1:Germany VX1:Germany VRTX:Austria

Address

50 Northern Avenue, Boston, MA, USA, 02210

Website

https://www.vrtx.com

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals Headlines

No Headlines